Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Advanced Search

Search

You could also try: inside layer (24), coating (68), liner (5)

Brexucel - Cyclophosphamide (500) - Fludarabine (30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY MCL – BREXUCEL – CYCLOPHOSPHAMIDE (500) – FLUDARABINE (30) This regimen will only be
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Brexucel-Cyclophosphamide-500-Fludarabine-30.pdf

Telephoning Results and Ranges

Description: University Hospital Southampton NHS Foundation Trust LABORATORY MEDICINE G3.2 Telephoning Results and Ranges G3.2 3.2 TELEPHONING RESULTS AND
Url: /Media/UHS-website-2019/Docs/Services/Pathology/Lab-med/Telephoning-Results-and-Ranges.pdf

BRC NMAHP researcher initiation internship award checklist 2023

Description: Name: Proposed Project Title: Contact details: Criteria Email: Mobile: 1. Registration with an appropriate UK regulatory and professional body: Evidence submitted
Url: /Media/Southampton-Clinical-Research/Downloads/BRC-NMAHP-researcher-initiation-internship-award-checklist-2023.pdf

Cytarabine(SC)-Venetoclax

Description: Chemotherapy Protocol Acute Myeloid Leukaemia CYTARABINE (SC) - VENETOCLAX Regimen  AML – Cytarabine (SC) -Venetoclax Indication  Newly diagnosed acute myeloid leukaemia (AML).  Patient
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/AML/CytarabineSC-Venetoclax.pdf

Atezolizumab-Bevacizumab

Description: Chemotherapy Protocol Hepatocellular Cancer ATEZOLIZUMAB-BEVACIZUMAB Regimen  HCC-Atezolizumab-Bevacizumab Indication  Atezolizumab in combination with bevacizumab for the first-line systemic
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Hepatobiliary/Atezolizumab-Bevacizumab.pdf

Inotuzumab Ozogamicin

Description: Relapsed or refractory CD22-positive B-Cell acute lymphoblastic leukaemia.
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/ALL/Inotuzumab-Ozogamicin.pdf

Papers Council of Governors 20 July 2022

Description: Agenda attachments 1 CoG Agenda - 20.07.2022.docx Date Time Location Chair Agenda Council of Governors 20/07/2022 14
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Papers-Council-of-Governors-20-July-2022.pdf

Papers Council of Governors - 27 April 2022

Description: Date Time Location Chair Agenda Council of Governors 27/04/2022 14:00 - 16:00 Microsoft Teams Jane Bailey 1 Chair
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Papers-Council-of-Governors-27-April-2022.pdf

Durvalumab(28day-1500mg)

Description: Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (28 day – 1500mg) Regimen • NSCLC - Durvalumab (28 day – 1500mg) Indication • Durvalumab is
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab28day-1500mg.pdf

Visiting guidelines: Burley and Lyndhurst wards - patient information

Description: This factsheet outlines the visiting guidelines on the maternity wards at Princess Anne Hospital.
Url: /Media/UHS-website-2019/Patientinformation/Pregnancyandbirth/Visiting-guidelines-Burley-and-Lyndhurst-wards-3137-PIL.pdf

341 to 350 of 743

Previous … 33 34 35 36 37 … Next